These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38851782)

  • 1. Simultaneous screening of overexpressed genes in breast cancer for oncogenic drivers and tumor dependencies.
    Mofunanya A; Cameron ER; Braun CJ; Celeste F; Zhao X; Hemann MT; Scott KL; Li J; Powers S
    Sci Rep; 2024 Jun; 14(1):13227. PubMed ID: 38851782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity.
    Maric G; Annis MG; MacDonald PA; Russo C; Perkins D; Siwak DR; Mills GB; Siegel PM
    Oncogene; 2019 Jun; 38(26):5294-5307. PubMed ID: 30914799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer.
    Xu C; Liu F; Xiang G; Cao L; Wang S; Liu J; Meng Q; Xu D; Lv S; Jiao J; Niu Y
    J Exp Clin Cancer Res; 2019 Jun; 38(1):238. PubMed ID: 31171012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of protumorigenic pathways by insulin like growth factor binding protein2 and its association along with β-catenin in breast cancer lymph node metastasis.
    Sehgal P; Kumar N; Praveen Kumar VR; Patil S; Bhattacharya A; Vijaya Kumar M; Mukherjee G; Kondaiah P
    Mol Cancer; 2013 Jun; 12():63. PubMed ID: 23767917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of BAG‑1 in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway.
    Lu S; Du Y; Cui F; Feng X; Ma Y; Liu H
    Oncol Rep; 2019 Mar; 41(3):1901-1910. PubMed ID: 30747221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YBX1/lncRNA SBF2-AS1 interaction regulates proliferation and tamoxifen sensitivity via PI3K/AKT/MTOR signaling in breast cancer cells.
    Hussain SA; Venkatesh T
    Mol Biol Rep; 2023 Apr; 50(4):3413-3428. PubMed ID: 36754932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.
    Gomatou G; Trontzas I; Ioannou S; Drizou M; Syrigos N; Kotteas E
    Mol Biol Rep; 2021 Jan; 48(1):915-925. PubMed ID: 33409716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression.
    Hu Y; Zhu Q; Tang L
    PLoS One; 2014; 9(3):e92099. PubMed ID: 24637915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-1229 overexpression promotes cell proliferation and tumorigenicity and activates Wnt/β-catenin signaling in breast cancer.
    Tan Z; Zheng H; Liu X; Zhang W; Zhu J; Wu G; Cao L; Song J; Wu S; Song L; Li J
    Oncotarget; 2016 Apr; 7(17):24076-87. PubMed ID: 26992223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.
    Paul R; Luo M; Mo X; Lu J; Yeo SK; Guan JL
    Breast Cancer Res; 2020 Jun; 22(1):59. PubMed ID: 32493400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CK1epsilon is required for breast cancers dependent on beta-catenin activity.
    Kim SY; Dunn IF; Firestein R; Gupta P; Wardwell L; Repich K; Schinzel AC; Wittner B; Silver SJ; Root DE; Boehm JS; Ramaswamy S; Lander ES; Hahn WC
    PLoS One; 2010 Feb; 5(2):e8979. PubMed ID: 20126544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.
    Gonugunta VK; Sareddy GR; Krishnan SR; Cortez V; Roy SS; Tekmal RR; Vadlamudi RK
    Mol Cancer Ther; 2014 Jun; 13(6):1578-88. PubMed ID: 24688046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.
    Li D; Ji H; Niu X; Yin L; Wang Y; Gu Y; Wang J; Zhou X; Zhang H; Zhang Q
    Cancer Sci; 2020 Jan; 111(1):47-58. PubMed ID: 31710162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long Non-Coding RNA (lncRNA) 91H Confers Tamoxifen Resistance in ER+ Breast Cancer Cells through Inhibiting mTOR Signaling Pathway.
    Lv ZY; Mo QP; Tang HC; Zheng SS
    Ann Clin Lab Sci; 2022 Nov; 52(6):947-955. PubMed ID: 36564063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/β-catenin signaling pathway by regulating WNT2.
    Xiu DH; Liu GF; Yu SN; Li LY; Zhao GQ; Liu L; Li XF
    J Exp Clin Cancer Res; 2019 Feb; 38(1):94. PubMed ID: 30791958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TMEM176B Regulates AKT/mTOR Signaling and Tumor Growth in Triple-Negative Breast Cancer.
    Kang C; Rostoker R; Ben-Shumel S; Rashed R; Duty JA; Demircioglu D; Antoniou IM; Isakov L; Shen-Orr Z; Bravo-Cordero JJ; Kase N; Cuajungco MP; Moran TM; LeRoith D; Gallagher EJ
    Cells; 2021 Dec; 10(12):. PubMed ID: 34943938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of Long Non-Coding RNA UCA1 Increases the Tamoxifen Sensitivity of Breast Cancer Cells through Inhibition of Wnt/β-Catenin Pathway.
    Liu H; Wang G; Yang L; Qu J; Yang Z; Zhou X
    PLoS One; 2016; 11(12):e0168406. PubMed ID: 27977766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acylglycerol kinase promotes cell proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor.
    Wang X; Lin C; Zhao X; Liu A; Zhu J; Li X; Song L
    Mol Cancer; 2014 May; 13():106. PubMed ID: 24886245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.